236 related articles for article (PubMed ID: 37124495)
1. Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis.
Chen X; He F; Zhang W; Fu Y; Cao Z
Front Oncol; 2023; 13():1092969. PubMed ID: 37124495
[TBL] [Abstract][Full Text] [Related]
2. The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis.
Qiu Q; Deng C; Li H; Qiu J; Shen Z; Ding Y
Front Oncol; 2022; 12():999203. PubMed ID: 36452503
[TBL] [Abstract][Full Text] [Related]
3. A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues.
Huang Y; Liao C; Shen Z; Zou Y; Xie W; Gan Q; Yao Y; Zheng J; Kong J
Front Immunol; 2024; 15():1297542. PubMed ID: 38444854
[TBL] [Abstract][Full Text] [Related]
4. Inflammation-related research within the field of bladder cancer: a bibliometric analysis.
Deng Z; Tang N; Xiong W; Lei X; Zhang T; Yang N
Front Oncol; 2023; 13():1126897. PubMed ID: 37350946
[TBL] [Abstract][Full Text] [Related]
5. Global research trends in non-muscle invasive bladder cancer: Bibliometric and visualized analysis.
Deng S; Meng F; Wang L; Yang Z; Xuan L; Xuan Z; Wang J
Front Oncol; 2022; 12():1044830. PubMed ID: 36465379
[TBL] [Abstract][Full Text] [Related]
6. Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021).
Yang S; Zhao S; Ye Y; Jia L; Lou Y
Front Immunol; 2022; 13():952546. PubMed ID: 36090978
[TBL] [Abstract][Full Text] [Related]
7. Research hot spots and trends in endocrine-related adverse events caused by immune checkpoint inhibitors: a bibliometric analysis and visualization research.
Zhao J; Liu G; Yang X; Zhang C; Han B; Jiang M
Front Endocrinol (Lausanne); 2024; 15():1253832. PubMed ID: 38686201
[TBL] [Abstract][Full Text] [Related]
8. Knowledge-map analysis of bladder cancer immunotherapy.
Lv Z; Hou J; Wang Y; Wang X; Wang Y; Wang K
Hum Vaccin Immunother; 2023 Dec; 19(3):2267301. PubMed ID: 37903500
[TBL] [Abstract][Full Text] [Related]
9. Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis.
Huang Y; Chen Z; Shen G; Fang S; Zheng J; Chi Z; Zhang Y; Zou Y; Gan Q; Liao C; Yao Y; Kong J; Fan X
Hum Vaccin Immunother; 2024 Dec; 20(1):2318815. PubMed ID: 38419524
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for ocular melanoma: a bibliometric and visualization analysis from 1991 to 2022.
Tan Y; Lu Y; Chen S; Zou C; Qin B
Front Oncol; 2023; 13():1161759. PubMed ID: 37324010
[TBL] [Abstract][Full Text] [Related]
11. A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011-2021.
Zhang H; Shi Y; Ying J; Chen Y; Guo R; Zhao X; Jia L; Xiong J; Jiang F
Front Endocrinol (Lausanne); 2023; 14():1164692. PubMed ID: 37152956
[TBL] [Abstract][Full Text] [Related]
12. Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis.
Yuan Y; Su Y; Wu Y; Xue Y; Zhang Y; Zhang Y; Zheng M; Chang T; Qu Y; Zhao T
Front Oncol; 2023; 13():1229905. PubMed ID: 37671057
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
14. Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis.
Su Y; Ruan Z; Wang R; Hao S; Tang Y; Huang X; Gao T; Li Z; Chang T
Front Immunol; 2022; 13():998217. PubMed ID: 36248874
[TBL] [Abstract][Full Text] [Related]
15. Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis.
Zhang L; Zheng H; Jiang ST; Liu YG; Zhang T; Zhang JW; Lu X; Zhao HT; Sang XT; Xu YY
Int J Surg; 2024 Mar; 110(3):1699-1710. PubMed ID: 38181123
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events: A bibliometric analysis.
Jiang ST; Liu YG; Zhang L; Sang XT; Xu YY; Lu X
Front Immunol; 2022; 13():1096806. PubMed ID: 36591239
[TBL] [Abstract][Full Text] [Related]
17. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study.
Shen J; Shen H; Ke L; Chen J; Dang X; Liu B; Hua Y
Front Immunol; 2022; 13():815575. PubMed ID: 35173728
[TBL] [Abstract][Full Text] [Related]
18. Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Broughton EI; Gooden KM; Mycock KL; Rajkovic I; Taylor-Stokes G
BMC Urol; 2022 Feb; 22(1):27. PubMed ID: 35219307
[TBL] [Abstract][Full Text] [Related]
19. Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.
Cheng K; Zhang H; Guo Q; Zhai P; Zhou Y; Yang W; Wang Y; Lu Y; Shen Z; Wu H
Front Immunol; 2022; 13():975695. PubMed ID: 36148235
[TBL] [Abstract][Full Text] [Related]
20. Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis.
Yang Y; Wang F
Front Oncol; 2022; 12():983892. PubMed ID: 36465399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
